Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh

Hussain et al., International Journal of Molecular and Immuno Oncology, doi:10.25259/IJMIO_30_2020, Dec 2020
https://c19ivm.org/hussain.html
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 24 countries.
No treatment is 100% effective. Protocols combine treatments.
5,700+ studies for 135 treatments. c19ivm.org
Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again.
Hussain et al., 11 Dec 2020, preprint, 3 authors.
Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh
Syed Md Akram Hussain, Md Shuayb, Mahmudur Rahman
International Journal of Molecular & Immuno Oncology, doi:10.25259/ijmio_30_2020
is is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
References
Caly, Druce, Catton, Jans, Wagstaff, e FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Cortiula, Pettke, Bartoletti, Puglisi, Helleday, Managing COVID-19 in the oncology clinic and avoiding the distraction effect, Ann Oncol
Hussain, Shuayb, Rahman, Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh, Int J Mol Immuno Oncol, doi:10.25259/IJMIO_30_2020
Hussman, Cellular and Molecular Pathways of COVID-19 and Potential Points of erapeutic Intervention, Front Pharmacol
Maurya, A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients
DOI record: { "DOI": "10.25259/ijmio_30_2020", "ISSN": [ "2456-3994" ], "URL": "http://dx.doi.org/10.25259/IJMIO_30_2020", "alternative-id": [ "10.25259/IJMIO_30_2020" ], "article-number": "27", "author": [ { "affiliation": [ { "name": "Department of Oncology, Square Hospitals, West Panthapath, Dhaka, Bangladesh," } ], "family": "Hussain", "given": "Syed Md Akram", "sequence": "first" }, { "affiliation": [ { "name": "Vancouver Prostate Centre, Vancouver General Hospital, The University of British Columbia, Vancouver, Canada," } ], "family": "Shuayb", "given": "Md", "sequence": "additional" }, { "affiliation": [ { "name": "Emerging Infections Program, IDD, International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh," } ], "family": "Rahman", "given": "Mahmudur", "sequence": "additional" } ], "container-title": "International Journal of Molecular and Immuno Oncology", "container-title-short": "IJMIO", "content-domain": { "crossmark-restriction": true, "domain": [ "ijmio.com" ] }, "created": { "date-parts": [ [ 2020, 12, 2 ] ], "date-time": "2020-12-02T12:39:43Z", "timestamp": 1606912783000 }, "deposited": { "date-parts": [ [ 2023, 3, 20 ] ], "date-time": "2023-03-20T06:29:39Z", "timestamp": 1679293779000 }, "indexed": { "date-parts": [ [ 2023, 3, 20 ] ], "date-time": "2023-03-20T07:12:57Z", "timestamp": 1679296377498 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2021, 1, 8 ] ] }, "language": "en", "link": [ { "URL": "https://ijmio.com/outcome-of-ivermectin-and-doxycycline-in-cancer-patients-with-coronavirus-disease-2019-a-positive-experience-in-bangladesh/", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://ijmio.com/outcome-of-ivermectin-and-doxycycline-in-cancer-patients-with-coronavirus-disease-2019-a-positive-experience-in-bangladesh/", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "10894", "original-title": [], "page": "27-29", "prefix": "10.25259", "published": { "date-parts": [ [ 2021, 1, 8 ] ] }, "published-online": { "date-parts": [ [ 2021, 1, 8 ] ] }, "publisher": "Scientific Scholar", "reference": [ { "DOI": "10.1016/j.antiviral.2020.104787", "article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro", "author": "Caly", "doi-asserted-by": "publisher", "first-page": "104787", "journal-title": "Antiviral Res", "key": "10.25259/IJMIO_30_2020/ref-2", "volume": "178", "year": "2020" }, { "DOI": "10.3389/fphar.2020.01169", "article-title": "Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention", "author": "Hussman", "doi-asserted-by": "publisher", "first-page": "1169", "journal-title": "Front Pharmacol", "key": "10.25259/IJMIO_30_2020/ref-4", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.annonc.2020.03.286", "article-title": "Managing COVID-19 in the oncology clinic and avoiding the distraction effect", "author": "Cortiula", "doi-asserted-by": "publisher", "first-page": "553", "journal-title": "Ann Oncol", "key": "10.25259/IJMIO_30_2020/ref-5", "volume": "31", "year": "2020" } ], "reference-count": 3, "references-count": 3, "relation": {}, "resource": { "primary": { "URL": "https://ijmio.com/outcome-of-ivermectin-and-doxycycline-in-cancer-patients-with-coronavirus-disease-2019-a-positive-experience-in-bangladesh/" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh", "type": "journal-article", "update-policy": "http://dx.doi.org/10.25259/crossmark_policy", "volume": "6" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit